Jayne Swain
Leeds, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Temporary treatment cessation compared with continuation of tyrosine kinase inhibitors for adults with renal cancer: the STAR non-inferiority RCT.
Journal: Health technology assessment (Winchester, England)
Published: September 09, 2024
Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial.
Journal: The journal of pathology. Clinical research
Published: September 14, 2023
Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.
Journal: Thyroid : official journal of the American Thyroid Association
Published: August 11, 2023
NET-02: a randomised, non-comparative, phase II trial of nal-IRI/5-FU or docetaxel as second-line therapy in patients with progressive poorly differentiated extra-pulmonary neuroendocrine carcinoma.
Journal: EClinicalMedicine
Published: March 27, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial.
Journal: The Lancet. Oncology
Published: November 02, 2022
Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell Cancer.
Journal: Diagnostics (Basel, Switzerland)
Published: May 17, 2021
NET-02 trial protocol: a multicentre, randomised, parallel group, open-label, phase II, single-stage selection trial of liposomal irinotecan (nal-IRI) and 5-fluorouracil (5-FU)/folinic acid or docetaxel as second-line therapy in patients with progressive poorly differentiated extrapulmonary neuroendocrine carcinoma (NEC).
Journal: BMJ open
Published: February 08, 2020
Showing 1-8 of 8
Last Updated: 09/26/2026